For the quarter ended June 2026, West Pharmaceutical Services (WST Quick QuoteWST - Free Report) reported revenue of $872.3 million, up 13.8% over the same period last year. EPS came in at $2.37, compared to $1.84 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $836.8 million, representing a surprise of +4.24%. The company delivered an EPS surprise of +13.94%, with the consensus EPS estimate being $2.08.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Change in Organic Revenue: 12.7% versus 9.3% estimated by two analysts on average.
• Net Sales- Proprietary Products: $722.6 million versus the three-analyst average estimate of $688.29 million. The reported number represents a year-over-year change of +16.6%.
• Gross Profit- Proprietary Products: $308 million versus the three-analyst average estimate of $279.06 million.

View all Key Company Metrics for West Pharmaceutical here>>>

Shares of West Pharmaceutical have returned +5.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.